"10.1371_journal.pone.0052208","plos one","2012-12-20T00:00:00Z","Thomas F Benkert; Lena Dietz; Elena M Hartmann; Ellen Leich; Andreas Rosenwald; Edgar Serfling; Mathias Buttmann; Friederike Berberich-Siebelt","Department of Molecular Pathology, University of Würzburg, Würzburg, Germany; Institute of Pathology, University of Würzburg, Würzburg, Germany; Department of Neurology, University of Würzburg, Würzburg, Germany","Conceived and designed the experiments: FBS MB. Performed the experiments: TFB LD EMH EL FBS. Analyzed the data: TFB LD EMH EL AR ES MB FBS. Contributed reagents/materials/analysis tools: MB EMH EL AR. Wrote the paper: FBS MB.","M.B. received a travel grant from Biogen Idec, the manufacturer of natalizumab (Tysabri®), which was not related to this manuscript. Furthermore, he received travel grants, speakers fees and a research grant from Merck Serono, served on an advisory board for Almirall Hermal GmbH, and received research grants from Sanofi Aventis and Teva Pharmaceutical Industries Ltd. as well as from Novartis. The other authors declare no competing interests. Biogen Idec/Elan had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","12","Thomas F Benkert","TFB",8,FALSE,2,5,8,2,TRUE,TRUE,FALSE,0,NA,FALSE
